ClinicalTrials.gg
CompletedNCT03015948Updated Jul 3, 2018

A Single Dose Study of SHR4640 in Healthy Male Volunteers

A Phase 1 interventional study of SHR4640 and Placebo in Gout, sponsored by Atridia Pty Ltd.. Completed at 1 site in Australia. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-03.

Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, none under way, none of them phase 3. Gout · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
8th of 11
40 · median 50
Started
2016
with 1 other
Phase 1
7 of 11
none open now
Registered
3rd of 11
by date

Among the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd., this one is the 8th largest by enrollment, is one of 2 that started in 2016, is one of 7 in phase 1, and was the 3rd registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

None of the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Gout, anywhere →

Where they have run

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

This is a single-center, randomized, double-blind, placebo-controlled, single ascending-dose Phase I trial.

Read the detailed description

This study includes screening (Days -16 to -3), check-in (Day -2), enrollment (Day -1), dosing (Day 1), observational period (Days 2 to 3), discharge day (Day 4), and safety follow-up visit (Day 8). Forty eligible subjects will be enrolled into 4 dose cohorts (10 for each cohort), and every 10 subjects will be randomized in a 4:1 ratio to receive a single dose of either SHR4640 (n=8) or placebo (n=2).

03

Conditions studied

  • Gout

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, aged between 18 and 55 years, inclusive.
  2. Body weight ≥ 50 kg and between 18.0 to 30.0 kg/m2, inclusive.
  3. Screening sUA level from 0.24 to 0.42 mmol/L, inclusive.
  4. Considered generally healthy upon completion of medical history, full physical examination, vital signs, laboratory parameters (including thyroid function, coagulation and serological tests, hematology, creatinine kinase, biochemistry, and urinalysis), 12-lead , and abdominal ultrasound, as judged by the Investigator.
  5. Agrees to use a highly effective method of , i.e. condom and suitable contraception for your female partner e.g. diaphragm (double barrier), oral contraceptive or intrauterine contraceptive device during heterosexual intercourse or be non-heterosexually active, or practice sexual abstinence throughout the study period and for 30 days following study drug dosing, and must agree to refrain from sperm donation from Day -2 until at least 30 days following study drug dosing.
  6. Negative drug screen (including alcohol) at screening and on admission to clinical site.
  7. Able to understand the study procedures and the risks involved and must be willing to provide written before any study-related activity.

Exclusion criteria

Exclusion Criteria:

  1. History of to SHR4640 or its analogues.
  2. Screening sCr above .
  3. Screening , aspartate aminotransferase, total , or gamma glutamyl transferase > 1.5 × upper limit of normal.
  4. Positive result for .
  5. Positive result for surface antigen or virus antibody.
  6. History or presence of kidney stones.
  7. Acute or chronic illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial product to the subject.
  8. Undergone major surgery within 3 months of Day 1.
  9. Donated any blood or plasma in the past month or more than 400 mL within 3 months of Day 1.
  10. Has poor venous access and is unable to donate blood.
  11. Use of tobacco products within 30 days of Day 1.
  12. Heavy caffeine drinker (more than 5 cups or glasses of caffeinated beverages per day).
  13. History of drug and/or alcohol abuse in the last year.
  14. Consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150 mL] of wine, 12 oz of beer, or 1.5 oz of hard liquor).
  15. Consumes grapefruit and/or poppy seed within 5 days of Day 1.
  16. Cannot refrain from heavy exercises, tobacco products, alcohol, grapefruit, and/or poppy seed from Day -2 to Day 4.
  17. Use of any of the following, unless agreed as nonclinically relevant by the Investigator and the Sponsor:
  1. Prescription medication within 2 weeks of Day 1. 2) Over-the-counter medication within 1 week of Day 1. 3) Use of any over the-counter, nutraceuticals, or prescription medications that might interfere with the absorption, distribution, metabolism, or excretion of SHR4640 (proton-pump inhibitor, fluconazole, indomethacin, ranitidine, flurbiprofen, probenecid, aprepitant, etc.) within 1 month of Day 1.
  1. Received the last dose of a study drug (or treatment with a medical device) within 30 days or 5 T1/2 (whichever is longer) of the study drug of Day 1 or are currently participating in another study of a study drug (or medical device).
  1. Any other medical or psychological condition, which in the opinion of the Investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or to complete the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    2.5mg SHR4640

    10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 2.5 mg SHR4640 (n=8) or placebo (n=2)

    Drug: SHR4640

  • Experimental
    10mg SHR4640

    10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 10mg SHR4640 (n=8) or placebo (n=2) 10mg.

    Drug: SHR4640

  • Experimental
    20mg SHR4640

    10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 20mg SHR4640 (n=8) or placebo (n=2) .

    Drug: SHR4640

  • Experimental
    Placebo

    For each dose cohort, 10 subjects will be randomized in a 4:1 ratio to receive a single dose of either SHR4640 (n=8) or placebo (n=2)

    Drug: Placebo

  • Experimental
    5mg SHR4640

    10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 5 mg SHR4640 (n=8) or placebo (n=2)

    Drug: SHR4640

Interventions

  • a single dose of SHR4640 (n=8) for each dose cohort

  • DrugPlacebo

    a single dose of placebo (n=2) for each dose cohort .

06

What researchers measure

Primary outcomes

  1. Assess safety and tolerability of SHR 4640 over 11days including AEs, laboratory safety variables (including hematology, creatinine kinase (CK), biochemistry, and urinalysis), physical examinations, vital signs, and 12-lead electrocardiograms (ECGs)

    Time frame: 11 days

Secondary outcomes

  1. Assess Pharmacokinetics (PK) Plasma parameter Area under the concentration-time curve (AUC) from zero to 24 and 72 hours postdose and from zero to infinity.

    Time frame: from time of dosing to 72 hours

  2. Assess Pharmacokinetics (PK) Plasma parameter Time to maximum concentration.

    Time frame: from time of dosing to 72 hours

  3. Assess Pharmacokinetics (PK) Plasma parameter Maximum concentration.

    Time frame: from time of dosing to 72 hours

  4. Assess Pharmacokinetics (PK) Plasma parameter Terminal elimination half-life (T1/2).

    Time frame: from time of dosing to 72 hours

  5. Assess Pharmacodynamics (PD) parameter Actual and percent changes in serum uric acid (sUA )from baseline.

    Time frame: from time of dosing to 72 hours

  6. Assess Pharmacodynamics (PD) parameter urinary uric acid concentration (uUA): actual and percent changes from baseline.

    Time frame: from time of dosing to 72 hours

  7. Assess Pharmacodynamics (PD) parameter urinary uric acid excretion (eUA): actual and percent changes from baseline.

    Time frame: from time of dosing to 72 hours

  8. Assess Pharmacodynamics (PD) parameter Uric acid renal clearance (UaCl): actual and percent changes from baseline

    Time frame: from time of dosing to 72 hours

07

Study locations

1 site
  • Atridia Pty Limited
    Sydney, New South Wales 2000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Nov 2016, 2 months.

Of 37 industry-sponsored phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 2 months is below that.

Counting every sponsor, half of 40 studies reached it within 6 months; a quarter within 1 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2016
First posted
Jan 10, 2017
StartActual
Sep 22, 2016
Primary completionActual
Nov 23, 2016
CompletionActual
Nov 23, 2016
Last update
Jul 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03015948
Lead sponsor
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Jan 10, 2017
Start date
Sep 22, 2016
Primary completion
Nov 23, 2016
Completion
Nov 23, 2016
Last update
Jul 3, 2018

Study contacts

Sam Salman, B.Sc,BMBS
principal investigator · Linear Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruzinurad

Start the discussion